Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Century Therapeutics (IPSC)
NASDAQ:IPSC
RESEARCH TOOLSreports
Holding IPSC?
Track your performance easily
IPSC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.90 - $5.51
Previous CloseN/A
Volume712.78K
Average Volume (3M)666.51K
Market Cap
$79.52M
Enterprise Value$1.33M
Total Cash (Recent Filing)$81.54M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Mar 13, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding85,029,045
10 Day Avg. Volume550,798
30 Day Avg. Volume666,514
Standard Deviation0.29
R-Squared0.09
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.83
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit0.59
Enterprise Value/Ebitda-0.01
Forecast
1Y Price Target
$6.67Price Target Upside609.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Century Therapeutics News
PremiumCompany Announcements
Century Therapeutics Unveils Advances in Cell Therapies
PremiumCompany Announcements
Century Therapeutics Faces Termination of BMS Agreement
PremiumCompany Announcements
Century Therapeutics Reports Q3 Results & Strategic Updates
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCentury reported two complete responses and three partial responses in patients treated at the highest dose level in the ongoing ELiPSE-1 trial.
Strategic DevelopmentThe company's strategy includes developing NK cell, γδ-T cell, and αβ-T cell therapies, enhancing its iPSC-derived cell therapy platform.
Therapeutic PotentialThe therapeutic potential and dosing flexibility of Century Therapeutics' Allo-Evasion technology promises superior clinical outcomes with CNTY-101 in autoimmune diseases.
Bears Say
Collaboration TerminationBMS' decision to discontinue their collaboration agreement with Century is disappointing and attributed to 'an internal corporate portfolio prioritization process.'
Data And Development DelaysCentury has suspended timing guidance on initial Phase 1 (CALiPSO-1) data, which was previously expected by year-end 2024.
Market ConstraintsCentury Therapeutics has reduced its peak worldwide sales model for CNTY-101 from $3.4B to $2.0B due to market constraints.
---
Ownership Overview
3.40% Insiders
6.26% Mutual Funds
29.27% Other Institutional Investors
55.82% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IPSC FAQ
What was Century Therapeutics’s price range in the past 12 months?
Century Therapeutics lowest stock price was $0.90 and its highest was $5.51 in the past 12 months.
What is Century Therapeutics’s market cap?
Century Therapeutics’s market cap is $79.52M.
When is Century Therapeutics’s upcoming earnings report date?
Century Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 54 days.
How were Century Therapeutics’s earnings last quarter?
Century Therapeutics released its earnings results on Nov 05, 2024. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.451 by $0.081.
Is Century Therapeutics overvalued?
According to Wall Street analysts Century Therapeutics’s price is currently Undervalued.
Does Century Therapeutics pay dividends?
Century Therapeutics does not currently pay dividends.
What is Century Therapeutics’s EPS estimate?
Century Therapeutics’s EPS estimate is -0.41.
How many shares outstanding does Century Therapeutics have?
Century Therapeutics has 85,029,045 shares outstanding.
What happened to Century Therapeutics’s price movement after its last earnings report?
Century Therapeutics reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.451. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of Century Therapeutics?
Currently, no hedge funds are holding shares in IPSC
---
Century Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (609.57% Upside)
$6.67 (609.57% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 66%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $22.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.34%
12-Months-Change
Fundamentals
Return on Equity
-62.61%
Trailing 12-Months
Asset Growth
-2.25%
Trailing 12-Months
Company Description
Century Therapeutics
Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.
---
IPSC Stock 12 Month Forecast
Average Price Target
$6.67
▲(609.57% Upside)
Technical Analysis
Adaptive Biotechnologies
―
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering IPSC
1 Year
1 Year Success Rate
2/18 ratings generated profit
1 Year Average Return
-40.94%
reiterated a buy rating 2 months ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -40.94% per trade.
---